Solutions for Pharma Process
From early process design to tech transfer, we deliver AI-led modeling and digital workflows that cut experiments and accelerate market entry.
Proven Results Across the Pharma Industry
Up to 90%
Experiment Reduction
$1M–$100M+
Engagement Value
US + EU + APAC
Global Delivery
Process development drives 25% of drug R&D cost and can delay market launch by two years
Challenges We Address
Siloed data and manual experimentation.
High cost of wet-lab work and long timelines.
Lack of standardized, reusable models.
Regulatory & business pressure across CMC and MSAT.
Model-based & AI-Powered Solutions Across R&D
Research
Development
Manufacturing
Pre-Clinical / Early Design Selection
Reaction, solubility & crystallization modeling
Material property prediction & data-driven screening
Cell line development & expression optimization
AI-resisted design
Foundational data capture
Process Development
Digital design workflows
Process model libraries for small & large molecules
Model-based design space exploration
In-silico experimentation & virtual process optimization
AI-powered risk assessments
Scale-Up & Tech Transfer
Scale-dependent simulation
Digital-twins for robustness studies
Tech transfer workflows
Scenario simulation & risk-based decision support
Knowledge capture & control strategy definition
Commercial Manufacturing
AI-enabled predictive control & anomaly detection
Process monitoring & advanced analytics
Digital twins for operations & performance optimization
Continuous verification & adaptive process control
Simplifying all therapeutic modalities
Our platform is designed to delivering all therapeutic modalities, with libraries of workflows structured to handle any of them effectively.
Small Molecule
Core treatments with precise targeting and established efficacy.
Oligonucleotides
Next-gen therapies using synthetic DNA or RNA fragments.
Biopharm & Sterile
Advanced biological therapies and sterile formulations for critical care.
Vaccines
Protective immunizations harnessing cutting-edge biotechnological advances.
Small Molecule
Core treatments with precise targeting and established efficacy.
Oligonucleotides
Next-gen therapies using synthetic DNA or RNA fragments.
Biopharm & Sterile
Advanced biological therapies and sterile formulations for critical care.
Vaccines
Protective immunizations harnessing cutting-edge biotechnological advances.
Case study
Connecting innovative teams and impactful products
Global Biopharmaceutical Leader
How Did ModelFlow’s End-to-End Digital Twin for Reactive Crystallization, Filtration, Washing, and Drying Accelerate the Development of a Second-Generation On-Market Blockbuster
80+
Lab experiments replaced through in-silico simulation
$200M
Informed a $200M facility investment decision
3+
Months saved via accelerated digital optimization
2L - 10,000L
Scale-up achieved digitally, eliminating 12 experiments at scale
Top 5 Global Healthcare Company
PolyModels Hub derives actionable insights from process, lab, and operations data to enhance yield and reduce suboptimal production.
50+
Suboptimal batches identified, representing ~10% of yearly production
$60M/year
Estimated annual value captured after implementing process changes
4+
Manufacturing sites achieving reproducible results through standardized models
150+
Process days recovered by avoiding rework of suboptimal batches
Leading European Pharmaceutical Company
How Does ModelFlow’s End-to-End Modeling Drive Results for a New Continuous Manufacturing Process of a Pipeline Blockbuster?
100+
Lab experiments reduced using in-silico runs
$3M
Development cost savings
3+
Months saved in development time
10+
Large-scale batch runs avoided
Top 5 Global Healthcare Company
How Did ModelFlow’s Digital Workflows Optimize Protein A Resin Usage and Accelerate Scale-Up for a Second-Generation Biologic?
4-Cycle
Optimized plan extending resin productivity while safeguarding resin life
$2M/year
Savings achieved through in-silico optimization of resin cycles
4
Large-scale campaign time saved via virtual DoE and risk analysis
2
Only two confirmatory experiments required for process validation
Our own process
01
Discovery and scoping
02
Model-Based Workflow Design
03
Collaborative Implementation
04
Democratization Through Apps
05
Evaluate Impact & Scale Success
01
Discovery and scoping
.
.
.
.
02
Model-Based Workflow Design
.
.
.
.
03
Collaborative Implementation
.
.
.
.
04
Democratization Through Apps
.
.
.
.
05
Evaluate Impact & Scale Success
Bringing life-changing medicines to people, safer and better
Why Polymodels Hub
Deep CMC and MSAT expertise from top pharma (GSK, Eli Lilly, Astrazeneca, J&J and more).
ModelFlow, our platform for physics-informed and AI-powered workflows.
Proven impact: up to 90% experiment reduction, six- to seven-figure contracts.
SOC 2 Type II and ISO 27001 certified for enterprise-level security and trust.
Certifications
SOC 2 Type I
Ecovadis
GDPR (In progress)
ISO27001 (In progress)
Accelerate pharma
process development.
Transform lives.
© Copyright 2025
Branded & Designed by HØLY™